Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Rating) was the target of a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 300,700 shares, a decline of 16.3% from the April 30th total of 359,100 shares. Currently, 5.1% of the shares of the company are short […]
MIAMI, Jan. 31, 2023 (GLOBE NEWSWIRE) Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused.